「egfr」に関連した動画の一覧

	VEGF and EGFR pathways in detail: Target for new therapies against cancer  Mechanism of action of VEGF (vascular endothelial growth factor) and EGFR (epidermal growth factor receptor) signalling pathways. Mécanisme d'action des voies de signalisation du VEGF et de l'EGFR. EFP Website: www.efp-online.org. European Fellowship for Pharmacists 2010年07月14日再生回数 27795
	The Highs and Lows of EGFR  The binding of epidermal growth factor (EGF) induces dimerization and activation of its receptor, EGFR. Watch as Mark Lemmon and Diego Alvarado take you on a brief, personally guided tour of their findings that low-affinity receptors are generated by asymmetric ligand binding and negative cooperativity. 2010年08月04日再生回数 3260
	EGFR mutation testing recommended for certain lung cancer patients  NEW YORK (Reuters Health) -- For patients with advanced, untreated non-small-cell lung cancer, the American Society of Clinical Oncology recommends that the tumor be tested for genetic mutations in the epidermal growth factor receptor (EGFR), to see if first line treatment should be with an EGFR tyrosine kinase inhibitor or combination chemotherapy. For more information, please visit: www.thedoctorschannel.com 2011年07月22日再生回数 564
	EGFR induced radiotherapy resistance in tumour cells  Prof Hans Peter Rodemann speaks about his work investigating how inhibition of the EGFR pathway induces resistance to radiotherapy in tumour cells. This research has shown that this signalling pathway induces resistance by activating DNA repair mechanisms. The EGFR receptors are themselves activated by ionising radiation, although the precise mechanisms of this is not yet fully understood. Prof Rodemann explains what is known of the mechanism, what further research he is planning and highlights some of the other key research from the field of radiobiology. Prof Hans Peter Rodemann of the University of Tübingen in Germany speaking to ecancer.tv at ESTRO 2010 2010年10月07日再生回数 225
	AACR 2009: Genetic influences in response to EGFR for metastatic colorectal cancer  Frederica Di Nicolantonio, Pharm.D., Ph.D., research fellow, Laboratory of Molecular Genetics, The Institute for Cancer Research and Treatment, University of Turin Medical School, speaking at AACR 2009, Denver: BRAF, PIK3CA and KRAS Mutations and Loss of PTEN Expression Impair Response to EGFR-Targeted Therapies in Metastatic Colorectal Cancer 2009年10月29日再生回数 504
	Understanding EGFR T790M mutations | Dana-Farber Cancer Institute  Dr. Geoffrey Oxnard describes a study that aims to identify non-smoking lung cancer patients who have a rare EGFR mutation, called T790M, in the germline. Dr. Oxnard is heading the study in collaboration with the Addario Lung Cancer Medical Institute (ALCMI), leading lung cancer research centers, and commercial gene-testing laboratories. 2012年03月21日再生回数 85
	GRACEcast-068_Lung-Cancer_Sequist on Acquired Resistance to EGFR  cancergrace.org Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it. 2011年07月26日再生回数 202
	Manitoba Renal Program - eGFR: Case2 - Hematuria  This fictional Case Study discusses a patient with hematuria. Disclaimer This video contains information and resources intended for use by physicians and other healthcare professionals in the Province of Manitoba. The information is not designed or intended for the general public and should not be considered, or used as a substitute for, medical advice. Individuals are advised to always seek the advice of a physician or other qualified health care provider for specific information on personal health matters. Resources and information in this video (the "Resources") are based on scientific evidence current as of the date issued and are subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Any person consulting or applying the Resources is expected to use independent medical judgment and expertise in the context of individual clinical circumstances. Winnipeg Regional Health Authority and the Manitoba Renal Program make no representation or guarantees of any kind whatsoever regarding the content or use or application of the Resources and specifically disclaim any responsibility for their application or use in any way. 2011年03月17日再生回数 229
	Dr. Scagliotti on Mechanisms of Resistance to EGFR TKIs  Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, explains the main mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI). Resistance to EGFR TKIs are caused by two main mechanisms, the first is an EGFR kinase domain mutations called T790M that occurs in approximately 50% of resistance. The second is a C-MET amplification that is present in 20% of cases. As more research is conducted further mechanism of resistance will be discovered. A number of agents are currently under investigation that can engage the resistant tumors. Trial results were recently released showing a benefit for T790M patients treated with Afatinib (BIBW 2992) and Cetuximab (Erbitux). This field is constantly involving and new drugs are still under investigation. 2011年10月08日再生回数 158
	EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma  www.curemeso.org Jason Foster, MDpresents at the International Symposium on Malignant Mesothelioma. This conference presented by the Mesothelioma Applied Research Foundation, took place in Washington DC in June 2010. To view all presentations or for more information, visit curemeso.org 2010年07月07日再生回数 256